Reperfusion injury is responsible for an important part of myocardial infarct establishment due notably to triggering cardiomyocytes death at the first minutes of reperfusion. AZP-531 is an optimized analog of unacylated ghrelin currently in clinical development in several metabolic diseases.

In this study conducted by the Team 5 (Leader: M. Ovize), a potential cardioprotective effect of AZP-531 in ischemia/reperfusion (IR) and the molecular underlying mechanism(s) involved in this protection were investigated.

In vivo postconditioning with AZP-531 in C57BL6 mouse IR model decreased infarct size. Western blot analysis on areas at risk from the different mouse groups showed that AZP-531 activates Akt, ERK1-2 as well as S6 and 4EBP1, mTORC1 effectors. We also showed an inhibition of caspase 3 cleavage and Bax translocation to the mitochondria. AZP-531 also stimulated the expression of antioxidants and was capable of decreasing mitochondrial H2O2 production, contributing to the reduction of ROS accumulation. AZP-531 exhibits cardioprotective effect when administrated for postconditioning in C57BL6 mouse IR model. Treatment with AZP-531 rescued the myocardium from cell death at early reperfusion by stimulating protein synthesis, inhibiting Bax/caspase 3-induced apoptosis as well as ROS accumulation and oxidative stress induced necrosis. AZP-531 may prove useful in the treatment of IR injury.

basic research in Cardiology Journal


Rania Harisseh R.,  Bruno Pillot, Abdallah Gharib,  Lionel Augeul, Noelle Gallo-Bona, Rene Ferrera,  Joseph Loufouat, Thomas Delale, Soraya Allas, Thierry Abribat, Claire Crola Da Silva and Michel Ovize, Basic Research in Cardiology, dec. 2016; DOI 10.1007/s00395-016-0595-9 PubMed


Michel OVIZE

Equipe 5 – Laboratoire CarMeN